UroGen Q1: Zusduri Commercial Rollout Picks Up Steam — Position for a 2027 Profitability Path
UroGen is shifting from development to commercialization as ZUSDURI rollout accelerates. With market cap near $1.3B, negative EPS but improving commercial signals and elevated short interest, this is a directional long for investors who want exposure to a commercial-stage bladder cancer franchise heading toward profitability by 2027.